The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 39 | — | 20.1x | Near average | |
Growth | 55 | 927.9% | 5.6% | Near average | |
Quality | 6 | -193.7% | 7.6% | Below average | |
Safety | 42 | 0.4x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 59 | — | — | Near average | |
Sentiment | 62 | — | — | Near average |
Autolus Therapeutics plc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Autolus Therapeutics plc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analyst data for Autolus Therapeutics shows a state of complete stability in price targets over the past 30 days, with the average price target stabilizing at 8.87 dollars, representing a significant positive gap compared to the current price (1.65 dollars). This stability reflects continued confidence from the three analysts covering the stock, with limited dispersion in forecasts ranging between 7.6 and 11 dollars, indicating relative agreement on the expected intrinsic value despite the low current market price.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.